Agog Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.15 Cr
as on 15-11-2024
- Paid Up Capital ₹ 3.15 Cr
as on 15-11-2024
- Company Age 34 Year,
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 12.50 Cr
as on 15-11-2024
- Satisfied Charges ₹ 13.48 Cr
as on 15-11-2024
- Revenue 37.34%
(FY 2023)
- Profit 70.77%
(FY 2023)
- Ebitda 57.85%
(FY 2023)
- Net Worth 21.23%
(FY 2023)
- Total Assets 15.70%
(FY 2023)
About Agog Pharma
The Corporate was formerly known as Agog Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.15 Cr and a paid-up capital of Rs 3.15 Cr.
The company currently has active open charges totaling ₹12.50 Cr. The company has closed loans amounting to ₹13.48 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shenaz Damani, Aziz Damani, and Anil Pandey serve as directors at the Company.
- CIN/LLPIN
U24230MH1990PLC059515
- Company No.
059515
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
20 Dec 1990
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Agog Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shenaz Damani  | Director | 02-Jun-2006 | Current |
| Aziz Damani | Director | 20-Jun-2005 | Current |
Anil Pandey  | Whole-Time Director | 30-Sep-2005 | Current |
Financial Performance and Corporate Structure Insights of Agog Pharma.
Agog Pharma Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 37.34% increase. The company also saw a substantial improvement in profitability, with a 70.77% increase in profit. The company's net worth Soared by an impressive increase of 21.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agog Pharma?
In 2023, Agog Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 May 2019 | ₹12.50 Cr | Open |
State Bank Of India Creation Date: 26 Nov 2007 | ₹9.90 Cr | Satisfied |
State Bank Of India Creation Date: 21 Aug 2003 | ₹1.40 Cr | Satisfied |
How Many Employees Work at Agog Pharma?
Agog Pharma has a workforce of 88 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agog Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agog Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
